Oat COM passes in vivo trial

The trial confirmed Oat Cosmetics' extruded colloidal oatmeal ingredient's anti-irritant capability

Oat Cosmetics has released the results of an in vivo clinical trial for Oat COM, its extruded colloidal oatmeal ingredient, which it says has confirmed its anti-irritant capability.

The trial was carried out on 15 healthy adult subjects, using an occlusive skin patch over a period of ten days. Two skin areas on the volar forearms were pre-irritated using a 0.5% sodium dodecyl sulphate solution, with one area covered with an patch coated with 0.6% Oat COM and the other an uncoated control. The test sites were assessed at day 0, after 24 hours and after five days, and the rate of recovery compared.

Oat Cosmetics said the results showed that Oat COM supported the increased repair rate of the skin, and showed statistically significant better recovery than the control site on Day 5 for assessments of skin hydration, skin cracking and visual erythema. The company explained that the effect is likely to have been caused by the interaction between the oat betaglucan and antioxidants (avenanthramides) contained within the colloidal oatmeal.

It also added that Oat COM’s patented process enhances the bio-availability of these molecules, making Oat COM an ideal ingredient for inclusion in products where soothing and moisturising properties are important.

Featured Companies

Oat Cosmetics (more information, website)